RGX-121-3102

RGX-121-3102 · REGENXBIO Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for RGX-121-3102, covering 2026-06-04 to 2026-06-04. Get the full timeline:

Most recent: Clinical Trial Update: RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome) [Phase 3]